| Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287) |
|---|
| 02/19/2004 | WO2003065987A3 Granzyme b inhibitors |
| 02/19/2004 | WO2003045974A3 Methods and compositions for derepression of iap-inhibited caspase |
| 02/19/2004 | WO2003027234A9 Small organic molecule regulators of cell proliferation |
| 02/19/2004 | WO2002048337A3 Secreted human proteins |
| 02/19/2004 | US20040034229 3,4-Di-substituted maleimide compounds as CXC chemokine receptor antagonists |
| 02/19/2004 | US20040034103 Cdc25 photophatase inhibitors |
| 02/19/2004 | US20040034093 Methods for enhancing motor performance and/or endurance |
| 02/19/2004 | US20040034090 Such as (7-chloro-2-methyl-1-(3-(methylsulphanyl)propyl)-1H-indol-3-yl)(2,3-dichloro-phenyl)methanone; cannabinoid receptors (cb2); G proteins coupled receptors |
| 02/19/2004 | US20040034069 Nitrogen-containing compounds and their use as glycine transport inhibitors |
| 02/19/2004 | US20040034055 For treating central nervous system disorders, immunomodulatory disorders, antimalaria, viral disease of Borna virus, Hepatitis; a 6-azatricyclo(6.3.1.01,6)dodecane derivatives |
| 02/19/2004 | US20040034018 2-amino-trihydroindole or tetrahydronapthalene-2-yl derivatives, useful for disease state associated with smooth muscle disorders, such as gastrointestinal and urogenital disorders |
| 02/19/2004 | US20040033952 Modified mature insulin variants and composition containing same |
| 02/19/2004 | US20040033951 Modified mature insulin variants and composition containing same |
| 02/19/2004 | US20040033946 Cell damage inhibitor |
| 02/19/2004 | US20040033945 Pharmaceutical compositions for treating asthenia or anaemia or for making a food supplement |
| 02/19/2004 | CA2495518A1 Bicyclic heteroaromatic compounds as kinase inhibitors |
| 02/19/2004 | CA2495516A1 Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia |
| 02/19/2004 | CA2495502A1 Methods for treating carbonic anhydrase mediated disorders |
| 02/19/2004 | CA2494865A1 Electrospun amorphous pharmaceutical compositions |
| 02/19/2004 | CA2494827A1 Cannabinoid receptor ligands |
| 02/19/2004 | CA2494026A1 Phosphodiesterase 4 inhibitors |
| 02/19/2004 | CA2493297A1 Methods to reprogram splice site selection in pre-messenger rnas |
| 02/18/2004 | EP1389206A2 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| 02/18/2004 | EP1389130A2 Use of osteopontin for the treatment and/or prevention of neurologic diseases |
| 02/18/2004 | EP1389099A1 Delivery of beta-blockers through an inhalation route |
| 02/18/2004 | EP1389098A1 Delivery of antipsychotics through an inhalation route |
| 02/18/2004 | EP1389097A1 Delivery of compounds for the treatment of parkinsons through an inhalation route |
| 02/18/2004 | EP1389096A1 Delivery of opioids through an inhalation route |
| 02/18/2004 | EP1389095A1 Delivery of antidepressants through an inhalation route |
| 02/18/2004 | EP1389094A1 Delivery of sedative-hypnotics trough an inhalation route |
| 02/18/2004 | EP1233786B1 Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance for the preparation of a medicament |
| 02/18/2004 | EP1178958B1 N-cyanomethyl amides as protease inhibitors |
| 02/18/2004 | EP1133494B1 8-azabicyclo 3.2.1]oct-2-ene and -octane derivatives |
| 02/18/2004 | CN1476448A Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents |
| 02/18/2004 | CN1476447A Aminothiazoles and their use as adenosine receptor antagonists |
| 02/18/2004 | CN1476442A Pyridine derivatives with IKB-kinase (IKK-beta) INhibiting activity |
| 02/18/2004 | CN1475224A Compound preparation of levocarnitin and adenosine triphosphate |
| 02/18/2004 | CN1475212A Compound preparation of levocarnitine and calcium pantothenate |
| 02/18/2004 | CN1475211A Compound preparation of levocarnitine and coenzyme Q10 |
| 02/18/2004 | CN1475207A Solid oral dosage mode containing walshaden and hydrochloric thizaine |
| 02/18/2004 | CN1475206A Medical composition containing micropowdery bicyclic medicine |
| 02/18/2004 | CN1138774C Substituted 6,6-hetero-bicyclic derivatives |
| 02/18/2004 | CN1138546C Certain 1,4,5-tri-substituted imidazole compounds useful as cytokine |
| 02/17/2004 | US6693108 Pyrimidinyl-guanidine derivatives |
| 02/17/2004 | US6693102 Pyridine-substituted pyrazolopyridine derivatives |
| 02/17/2004 | US6693096 Treatment of inflammation-associated disorders using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors |
| 02/12/2004 | WO2004013109A1 Resorcinol derivative |
| 02/12/2004 | WO2004012503A2 Compositions comprising muscle progenitor cells and uses thereof |
| 02/12/2004 | WO2003103604A3 Gamma lactams as prostaglandin agonists and use thereof |
| 02/12/2004 | WO2003086417B1 Use of pyrimidine nucleotides for the treatment of affections of the peripheral nervous system |
| 02/12/2004 | WO2003070968A3 RNA INTERFERENCE MEDIATED INHIBITION OF GASTRIC INHIBITORY POLYPEPTIDE (GIP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 02/12/2004 | WO2003059264A3 Methods for the induction of professional and cytokine-producing regulatory cells |
| 02/12/2004 | WO2003049723A3 Use of protease-activated receptor-2 inhibitor in the manifacture of a medicament for treating delayed hypersensitivity |
| 02/12/2004 | WO2003015710A3 Combined drug and csf removal therapies and systems |
| 02/12/2004 | WO2003010159A8 Piperidine derivatives as nmda receptor antagonists |
| 02/12/2004 | WO2002074346A3 Targeting chemical compounds to cells |
| 02/12/2004 | WO2002057454A3 Receptors and membrane-associated proteins |
| 02/12/2004 | WO2002053580A3 Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
| 02/12/2004 | US20040030114 Myostatin regulatory region, nucleotide sequence determination and methods for its use |
| 02/12/2004 | US20040030096 Novel human proteins, polynucleotides encoding them and methods of using the same |
| 02/12/2004 | US20040029964 Calcium formate for use as a dietary supplement |
| 02/12/2004 | US20040029954 Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease |
| 02/12/2004 | US20040029938 Medicaments |
| 02/12/2004 | US20040029937 Benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents |
| 02/12/2004 | US20040029935 Heterocyclic aromatic compounds useful as growth hormone secretagogues |
| 02/12/2004 | US20040029929 Aminoadamantane derivatives as therapeutic agents |
| 02/12/2004 | US20040029925 Central nervous system disorders; psychological disorders; gastrointestinal disorders |
| 02/12/2004 | US20040029912 Bicyclic derivatives |
| 02/12/2004 | US20040029904 Spiro(2H-1benzopyran-2,4'-piperidine) derivates as glycine transport inhibitors |
| 02/12/2004 | US20040029889 Bone disorders; antiarrhythmia agents; cardiovascular disorders |
| 02/12/2004 | US20040029869 Methods and compositions for treating or preventing sleep disturbances and associated illnesses using very low doses of cyclobenzaprine |
| 02/12/2004 | US20040029866 Polymerase enzyme inhibitors |
| 02/12/2004 | US20040029833 6-Mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block |
| 02/12/2004 | US20040029803 Binding to apoptosis cells |
| 02/12/2004 | US20040029801 Antiinflammatory agents; immunosuppressants; inflammatory bowel disease; antiarthritic agents; autoimmune diseases; administering drug and immunosuppressant |
| 02/12/2004 | US20040029132 Nucleic acid and amino acid sequences of drug metabolizing enzymes; used in diagnosis, treatment, and prevention of autoimmune/ inflammatory, cell proliferative, developmental, endocrine, eye, metabolic, and gastrointestinal disorders |
| 02/12/2004 | US20040029117 Methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the DNA |
| 02/12/2004 | US20040028734 Muscular disorders; antiproliferative agents; antiinflammatory agents |
| 02/12/2004 | US20040028684 Cancer diagnosis and assays for screening anti-cancer agents |
| 02/12/2004 | US20040028658 Methods of organ regeneration |
| 02/11/2004 | EP1387889A2 Kinases and phosphatases |
| 02/11/2004 | EP1387854A2 Sfrp and peptide motifs that interact with sfrp and methods of their use |
| 02/11/2004 | EP1231908B1 Pharmaceutical composition comprising a no donor compound and its use |
| 02/11/2004 | EP0936912B1 Inhibitors of cysteine protease |
| 02/11/2004 | CN1474812A (Dihydro) isoquinoline derivatives as phosphodiesterase inhibitor |
| 02/11/2004 | CN1474805A 2-amino-2-alkyl-5-heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 02/11/2004 | CN1474689A CDC25 phosphatase inhibitors |
| 02/11/2004 | CN1137712C Quick-action oral liquid for treating sprain and pull and its preparing method |
| 02/10/2004 | US6689922 Vitamin D analogues |
| 02/10/2004 | US6689906 Bicyclic amino acids as pharmaceutical agents |
| 02/10/2004 | US6689812 Can be administered with conventional drugs to treat psychiatric or central nervous disorders to improve their efficacy or reduce their side effects |
| 02/10/2004 | US6689790 Substituted triazolopyridine compounds |
| 02/10/2004 | US6689741 Biocompatible polymers, process for their preparation and compositions containing them |
| 02/10/2004 | US6689339 Freckles |
| 02/10/2004 | US6689299 Process for producing solid creatine dosage forms and dosage forms obtainable thereby |
| 02/10/2004 | US6688311 Method for determining effect of a clostridial toxin upon a muscle |
| 02/05/2004 | WO2004011468A1 Diazabicyclononane and -decane derivatives and their use as opioid receptor ligands |
| 02/05/2004 | WO2004011443A1 Pyrimidyl sulphone amide derivatives as chemokine receptor modulators |
| 02/05/2004 | WO2004011402A2 Novel arylimidazole derivatives, preparation and therapeutic uses thereof |
| 02/05/2004 | WO2004010995A1 Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthristis |